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Abstract The Rho/Rho-kinase pathway is considered im-
portant in the pathogenesis of sustained smooth muscle cell
contraction during cerebral vasospasm after aneurysmal
subarachnoid hemorrhage (SAH). The aims of this study
were to investigate whether combination treatment, with
pitavastatin as an inhibitor of RhoA and fasudil as an inhib-
itor of Rho-kinase, prevents the cerebral vasospasm. SAH
was simulated using the double-hemorrhage rabbit model,
and pitavastatin, or fasudil, or both (combination treatment)
were administrated. The basilar artery (BA) cross-sectional
area only in the combination treatment group was statisti-
cally larger than in the SAH group (p<0.05). BA Rho-
kinase, as measured by ELISA, was statistically reduced
only in the combination treatment group compared with
the SAH group (p<0.05). In the other two treatment groups,
pitavastatin or fasudil treatment group showed larger BA
cross-sectional areas and lower value for BA Rho-kinase,
but there were no statistically significant differences com-
pared with the SAH group. The expression of endothelial
nitric oxide synthase (eNOS), evaluated by immunohisto-
chemistry in the pitavastatin group and the combination
group, was higher than in the SAH group. Results indicate
that combination treatment could extensively prevent cere-
bral vasospasm due to the synergic effect of combining
pitavastatin and fasudil on the Rho/Rho-kinase pathway
and on eNOS.
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Introduction
Cerebral vasospasm after aneurysmal subarachnoid hemor-
rhage (SAH), which is thought to be caused by sustained
contraction of smooth muscle cells of the major cerebral
arteries, induces cerebral ischemia and affects subsequent
mortality and morbidity[1, 2]. Many intracellular signaling
transduction pathways are considered to be implicated in the
sustained contraction of smooth muscle cells during cerebral
vasospasm [3]. Of these, the Rho/Rho-kinase pathway has
been in focus as one of the main pathways [4, 5].
The G protein-coupled receptor is activated by several
clot-derived substances that alter the subarachnoid space
after SAH and that induce the activation of RhoA followed
by activation of Rho-kinase [6]. Rho-kinase inhibits the
activity of myosin light chain (MLC) phosphatase, resulting
in the activity of MLC kinase predominating over that of
MLC phosphatase. This leads to phosphorylation of MLC
and promotes the mutual sliding of actin and myosin [7, 8].
This point of view suggests that the Rho-kinase inhibitor,
fasudil (hydroxyfasudil), could be efficacious in preventing
cerebral vasospasm. However, clinical studies have revealed
that this efficacy is not remarkable [9, 10].
On the other hand, statin has recently been shown to
inhibit RhoA[11]. Statin inhibits HMG-CoA reductase, an
enzyme promoting the conversion of HMG-CoA to meva-
lonic acid, which results in the inhibition of cholesterol
biosynthesis. In addition, mevalonic acid, which is reduced
due to statin, leads to a decrease in the production of
M. Naraoka :A. Munakata :N. Matsuda :N. Shimamura :
H. Ohkuma (*)
Department of Neurosurgery, Hirosaki University
School of Medicine, 5 Zaifu-cho,
Hirosaki 036-8216, Japan
e-mail: ohkuma@cc.hirosaki-u.ac.jp
Transl. Stroke Res. (2013) 4:368–374
DOI 10.1007/s12975-012-0247-9
isopentenyl pyrophosphate and geranylgeranyl pyrophos-
phate (GGPP). GGPP geranylgeranylates Rho-GDP, which
is activated by Rho-GEF. Therefore, decreased GGPP indu-
ces the inhibition of RhoA [12, 13].
Statin has already been used in the prevention of vaso-
spasm, with the anticipation that its action would upregulate
endothelial nitric oxide synthase (eNOS) [14]. To date, this
effort has shown no evident efficacy in clinical studies [15].
Although neither fasudil nor statin show remarkable
effects in terms of preventing cerebral vasospasm as single
use, a combination of these drugs might show sufficient
effect through the strong suppression of the Rho/Rho-kinase
pathway, due to inhibition of RhoA by statin and the inhi-
bition of Rho-kinase by fasudil.
In order to elucidate any synergic effect in the prevention
of cerebral vasospasm, we performed an experimental study
using the rabbit SAH model.
Materials and Methods
Animal Population
All experimental protocols were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals,
from the National Institutes of Health (NIH) and approved
by the Hirosaki University Animal Research Committee
(M11-019).
All Japanese white rabbits used in the present study were
purchased from the Kitayama Labes Co., Ltd (Nagano,
Japan). They were maintained on standard pellets at the
Institute for Animal Experiments, Hirosaki University
School of Medicine. The temperature in both the feeding
and the operating room was maintained at about 25 °C.
Animal Experimental Design
Forty 12-week-old female Japanese white rabbits weighing
from 2.50 to 2.99 kg were operated. The animals were
assigned randomly to five groups; (1) sham group, physio-
logical saline injected into the cisterna magna twice and
animals killed on day 5 (n=8); (2) SAH group, SAH pro-
duced as described later and animals killed on day 5 (n=8);
(3) pitavastatin group, after production of SAH, animals
treated with pitavastatin (0.8 mgkg−1 day−1) by oral admin-
istration once a day from days 0 to 5 and killed on day 5 (n=
8); (4) fasudil group, after production of SAH, animals
treated with fasudil (hydroxyfasudil; 3.0 mg/kg) by intrave-
nous administration twice a day from days 0 to 5 and then
killed on day 5 (n=8); (5) combination group: after the
production of SAH, animals received combination treatment
by oral administration of pitavastatin (0.8 mgkg−1 day−1)
once a day and intravenous administration of fasudil
(hydroxyfasudil, 3.0 mg/kg) twice a day from days 0 to 5
and were then killed on day 5 (n=8).
In total, 59 animals were operated in this study, 8 in sham
group, 15 in SAH group, 12 in pitavastatin group, 13 in
fasudil group, and 11 in combination group. The mortality
rate due to SAH was about 47 % in SAH group, 33 % in
pitavastatin group, 38 % in fasudil group, and 27 % in
combination group, respectively.
Four rabbits in each group were killed using the
perfusion–fixation method for histological and immuno-
histochemical evaluation of the basilar arteries. The
other four rabbits in each group were killed without
perfusion–fixation and the basilar arteries were immedi-
ately removed and stored at −80 °C for protein analysis
by ELISA.
Induction of Experimental SAH
Experimental SAH was produced according to the two-
hemorrhage method as previously described [16]. The
rabbits were anesthetized with an intravenous injection
of pentobarbital (30 mg/kg) and an intramuscular injec-
tion of ketamine (20 mg/kg). After anesthesia, under
spontaneous breathing a 23-gauge butterfly needle was
inserted percutaneously into the cisterna magna. After
aspiration of 1.5 ml cerebrospinal fluid, the same
amount of nonheparinized arterial blood from the fem-
oral artery was slowly injected into the cisterna magna
for 1 min under aseptic technique. Rabbits were then
placed in a 30° head-down position for 30 min. After
recovery from anesthesia, they were returned to the
feeding room. Forty-eight hours afterwards (day 2), the
second experimental SAH was performed in the same
manner as the first. In the sham group, the same tech-
nique was applied, with the injection of sterile saline
instead of blood.
Perfusion–Fixation
On day 5, four rabbits in each group were deeply anesthe-
tized with an intravenous injection of high-dose pentobarbi-
tal (300 mg/kg) and an intramuscular injection of ketamine
(100 mg/kg). Perfusion-fixation was then performed. After
the thorax was opened, a cannula was immediately inserted
into the ascending aorta via the left ventricle. Subsequently,
the descending aorta was clamped, and the right atrium was
opened. Perfusion was begun with 500 ml heparinized
physiological saline (5000 U/500 ml) at 37 °C, followed
by 500 ml of phosphate-buffered 4 % paraformaldehyde
(pH 7.4) under a perfusion pressure of 75 mmHg. Finally,
the whole brain was carefully removed so as not to stretch or
injure the basilar artery.
Transl. Stroke Res. (2013) 4:368–374 369
Measurement of Basilar Artery Cross-section Area
The degree of cerebral vasospasm was evaluated by mea-
suring basilar artery lumen cross-sectional area. The
formalin-fixed and paraffin-embedded basilar artery sec-
tions (6 μm thick) were deparaffinized, hydrated, washed,
and stained with hematoxylin and eosin. Micrographs of the
basilar arteries were analyzed by using an Image J® version
1.45 (NIH). Cross-sectional areas of basilar arteries were
calculated from the perimeter of the luminal border and the
area contained within the boundaries of the internal elastic
lamina was neglected. For each vessel, three sequential
sections (midpoint of proximal, middle, and distal) were
taken, measured, and averaged. The mean ± SEM value
obtained for each artery was used as the final value for a
particular vessel.
Immunohistochemical Analysis for eNOS
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded sections to determine the immunoreac-
tivity of eNOS. Sections were deparaffinized and rehydrated
in graded concentrations of ethanol to distilled water. Sec-
tions were placed in EDTA buffer (pH 9.0), and heated in a
microwave oven for 15 min, then cooled at room tempera-
ture for 20 min and rinsed in PBS. Endogenous peroxidase
activity was blocked with 3 % H2O2 for 5 min, followed by
a brief rinse in distilled water and a 15-min wash in PBS.
Nonspecific protein binding was blocked by 5 % horse
serum. Sections were incubated with primary anti-eNOS
antibody (1:200 dilution, BD Biosciences) for 1 h at room
temperature, followed by a 15-min wash in PBS. Sections
were incubated with goat anti-rabbit IgG (1:500 dilution) for
60 min at room temperature. Diaminobenzidine was used as
the chromogen and counterstaining was performed with
hematoxylin.
ELISA Analysis for Rho A and Rho Kinase
The other four rabbits in each group were euthanized using
high dose pentobarbital (300 mg/kg) and intramuscular in-
jection of ketamine (100 mg/kg), and the basilar artery was
immediately removed, frozen in liquid nitrogen, and stored
at −80 °C until analysis.
When proteins were extracted after thawing at room
temperature and the vessel surface was cleaned in order to
remove the SAH, we disrupted the vessels by sonication,
taking care to avoid heat denaturation, with RIPA Lysis
Buffer (sc-24948, Santa Cruz). The debris was pelleted with
2,000×g centrifugation for 10 min, and the supernatant was
further centrifuged at 15,000×g for 15 min at 4 °C.
Using a protein assay kit (500-0002JA, BIO-RAD), pro-
tein concentration was measured by the standard microplate
assay method (bovine serum albumin for the calibration
curve included with the kit). After we uniformly revised
protein density for each group, we confirmed the density
of each group by measuring the concentration again. RhoA
was measured by the G-LISA™ RhoA Activation Assay
Biochem Kit™ (Luminescence Based, cat No. BK121, Cy-
toskeleton; control RhoA is included with the kit) at
490 nm. Rho-kinase was measured by the CycLex Rho-
kinase Assay Kit™ (Absorbance Based, cat No. CY-1160,
CycLex; control Rho-kinase is cat No. CY-E1160-1,
CycLex, sold separately) at 450 nm. The measurements
were carried out three times for both RhoA and Rho-
kinase, confirming reproducibility.
Statistical Analysis
Statistical analysis was performed using the JMP® (Ver-
sion 8; SAS Institute Inc., Cary, NC). Data are expressed
as mean ± SEM. In order to compare the two groups
expressed as the mean ± SEM, normal distribution is not
paired; we used the Kruskal–Wallis test, significance
determined at p<0.05.
Results
Evaluation of Cerebral Vasospasm and Vascular Patency
The cross sections of the basilar artery in each group,
determined by staining with hematoxylin and eosin and
observed under the light microscope, are shown in Fig. 1.
The cross-sectional areas of the basilar artery in the
SAH group were 67±19 μm2, which were statistically
significantly less as compared with those in the sham
group (Fig. 2). The cross-sectional areas of the basilar
artery in the pitavastatin group, fasudil group, and com-
bination group were 230±67, 220±15, and 320±51 μm2,
respectively. Although the cross-sectional areas in the
combination group showed a maximum value, there was
no statistically significant difference among the three
treated groups. The cross-sectional areas in the combina-
tion treatment group was significantly larger (p<0.05)
compared with those in the SAH group (Fig. 2).
Evaluation of Rho-A/Rho-kinase
RhoA in the SAH group were 1.34±0.1 ng/μl. The SAH
group showed a statistically significant increase in RhoA as
compared with the sham group (Fig. 3). RhoA in the pit-
avastatin group, fasudil group, and combination group were
0.82±0.106, 1.16±0.12, and 1.02±0.072 ng/μl, respective-
ly. RhoA was significantly decreased in the pitavastatin
group as compared with the SAH group (p<0.05). The
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fasudil group and the combination group showed some
decreases in RhoA as compared with the SAH group, but
statistically significant differences were not seen. And there
were no statistically significant differences among all three
treatment groups.
Rho-kinase in the SAH group were 0.354±0.067 units/
μl. The SAH group showed a statistically significant in-
crease in Rho-kinase as compared with the sham group
(Fig. 4). Rho-kinase in the pitavastatin group, fasudil group,
and combination group were 0.257±0.12, 0.227±0.057, and
0.146±0.058 units/μl, respectively. Only in the combination
treatment group showed a statistically significant compared
with the SAH group (p<0.05). The pitavastatin group and
the fasudil group showed some decreases in Rho-kinase as
compared with the SAH group, but statistically significant
differences were not seen, and there were no statistically
significant differences among all three treatment groups.
Evaluation of eNOS
In comparison to the sham group (Fig. 5A), no or less
staining of eNOS in the endothelial cell was seen in the
SAH group (Fig. 5B). In the pitavastatin (Fig. 5C) and
combination groups (Fig. 5E), eNOS staining increased as
Fig. 1 A Sham, B SAH, C pitavastatin, D fasudil, and E combination
treatment. Histopathological findings of the basilar artery were evaluated
with HE staining. In (B), corrugation of the internal elastic lamina was
found. In contrast, in all treatment groups (C–E), there was faint corruga-




























Fig. 2 The cross-sectional areas of the basilar artery. In the SAH
group, the mean ± SEM cross-sectional areas of the basilar artery were
statistically significantly reduced 4 days after SAH versus combination
treatment group among all the treatment groups (p<0.05, n=4 each).
The cross-sectional areas of the combination group were about the



















Fig. 3 RhoA expression. Expression of RhoA was significantly
inhibited in the vascular smooth muscle cells by ELISA (p<0.05;
versus SAH group, n=4 each) only in the pitavastatin group among
all the treatment groups. RhoA for the fasudil group showed no
inhibitory effect and the same degree of absorbance as the SAH group.
Although RhoA for the combination group was inhibited as compared
with the SAH group, a significant difference did not result
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compared with the SAH group. However, eNOS staining
was not seen in the fasudil group (Fig. 5D).
Discussion
The Rho/Rho-kinase pathway has been considered as play-
ing an important role in sustained contraction during cere-
bral vasospasm after aneurysmal SAH [5]. After SAH, it is
thought that the Rho/Rho-kinase pathway is activated by the
following process.
Initially, the G protein-coupled receptor is stimulated by
several substances present in the subarachnoid space after
SAH [17]. These include thrombin [18, 19], endothelin-1
[20, 21], oxyhemoglobin [17], sphingosine-1 phosphate [22,
23], PDGF [24, 25], TXA2 [26], etc. Stimulated Gα13,
among the G protein-coupled receptors, activates Rho-
GEF (guanine nucleotide exchange factor), which activates
RhoA by converting RhoA-GDP to RhoA-GTP. In turn,
phosphorylated RhoA results in the activation of Rho-
kinase [26]. Phosphorylated Rho-kinase inactivates MLC
phosphatase through phosphorylation of MLC phosphatase
target subunit 1 (MYPT1) and MLC phosphatase-specific
inhibitor, the 17 kDa PKC-potentiated protein phosphatase 1
inhibitor protein (CPI-17) [27, 28]. Furthermore, it has
recently been indicated that phosphorylated Rho-kinase
can phosphorylate MLC kinase at the Ser19 residue, which
is the site phosphorylated by Ca2+/calmodulin-dependent
MLC kinase [29]. Both inactivation of MLC phosphatase
and activation of MLC kinase result in sustained contraction
of smooth muscle cells.
Inhibition of the Rho/Rho-kinase pathway is therefore
considered to represent potential therapy preventing cerebral
vasospasm. Fasudil (hydroxyfasudil), a selective inhibitor of
Rho-kinase, was introduced in clinical use in 1995 in Japan.
In its original clinical randomized double blind trials using
placebo as control, it was revealed that fasudil significantly
reduced angiographically demonstrable vasospasm by 38 %
(from 61 % in the placebo group to 38 % in the fasudil


















Fig. 4 Rho-kinase expression. The expression of Rho-kinase was
significantly inhibited in the vascular smooth muscle cells by ELISA
(p<0.05; versus SAH group, n=4 each) only in the combination group.
Although Rho-kinase for the fasudil group was inhibited as compared
with the SAH group, a significant difference did not result
Fig. 5 A Sham, B SAH, C pitavastatin, D fasudil, and E combination
treatment. Histopathological findings for the basilar artery were eval-
uated with eNOS staining (the same expansion). In the pitavastatin and
combination treatment group, eNOS increased to the same extent as the
sham group (see arrow, eNOS expressed in brown by endothelium) in
comparison to the SAH group
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35 %) after SAH surgery[30]. In addition, fasudil is indicat-
ed to have pleomorphic (pleiotropic) effects for cerebral
vasospasm, such as protection from endothelial cell damage
and anti-inflammatory effects [31]. Several clinical studies
have shown that fasudil suppresses cerebral vasospasm and
the associated cerebral ischemic symptoms; however, it has
also been demonstrated as failing to show sufficient effect in
terms of preventing cerebral vasospasm as single use [9, 32].
On the other hand, the hydroxymethylglutaryl-CoA re-
ductase inhibitor, or statin, which is known to have a cho-
lesterol lowering effect, has recently been tried in the
prevention of cerebral vasospasm. In experimental studies,
statin was shown to ameliorate cerebral vasospasm by upre-
gulating eNOS [33]. Statin activates Akt, which upregulates
the activity of eNOS and enhances NO release from endo-
thelial cells and, as a result, statin ameliorates cerebral vaso-
spam [34]. However, in clinical studies, its effects in terms
of cerebral vasospasm have been controversial [35–37].
In addition to eNOS upregulation, in the fields of angi-
ology, it has been indicated that statin has several pleiotropic
actions that are considered beneficial in preventing cerebral
vasospasm, such as inhibiting endothelin-1, inflammation,
NADPH oxidase [38], and the caveolin-1 signaling path-
way, and, recently, RhoAwas also shown to be inhibited by
statin [12].
Therefore, we speculated that a combination treatment of
statin, for RhoA and eNOS, and fasudil, for Rho-kinase,
might suppress the Rho/Rho-kinase pathway more intensely
than the single use of statin or fasudil alone.
In this study, the factors examined were phosphory-
lated RhoA and phosphorylated Rho-kinase, which were
essential and important in evaluating the degree of ac-
tivation of the Rho/Rho-kinase pathway [4, 5], and of
eNOS, which increases the production of NO by endo-
thelial cells and is thought to be enhanced by statin or
fasudil [10, 34].
As a result, RhoAwas suppressed statistically significant-
ly by the administration of statin alone, which corresponds
to the results shown by Rashid and Rattan. However, in the
combination group, the reduction of RhoA was greater than
in the fasudil group but less than in the statin group, and no
statistically significant difference was shown as compared
with the SAH group. The reason for this is not clarified by
this study, but decreased activity of Rho-kinase induced by
fasudil may play a role as a feedback to reduce RhoA
activity [39]. These interactions between RhoA and Rho-
kinase should be clarified in detail in the future.
On the other hand, Rho-kinase activity was inhibited by
combination treatment. The combination group showed a
statistically significant depression activity for Rho-kinase,
suggesting that a combination of statin and fasudil could
achieve a synergic effect. Its reduction in activity by statin
may be increased by the depression of RhoA activity [12,
13], and its reduction in activity by fasudil was due to the
direct effect of fasudil on Rho-kinase [10].
Although eNOS expression after SAH is controversial
[40, 41], our study showed a reduction of eNOS expression
in the endothelial cells after SAH, and eNOS expression was
enhanced in the combination group as well as in the statin
group, although its expression was not enhanced in the
fasudil group.
Overall, prevention of cerebral vasospasm is superior in
the combination therapy group, reflecting its superior effect
in inhibiting Rho-kinase activity and maintaining the same
enhancement of eNOS as statin. Therefore, despite the in-
complete effects of statin or fasudil alone in the prevention
of cerebral vasospasm, a combination of these two drugs can
achieve adequate effects that should be tested in a clinical
study in the near future.
If, as suspected, combination treatment can greatly suppress
the Rho/Rho-kinase pathway and induce remarkable amelio-
ration of cerebral vasospasm, the Rho/Rho-kinase pathway
will prove to be one of the main pathways inducing sustained
contraction of smooth muscle cells during cerebral vasospasm.
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